Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ishmael Jaiyesimi(Beaumont Hospital, Royal Oak), David R. Spigel(Sarah Cannon), Hirva Mamdani(Wayne State University), Dharamvir Jain(University of Louisville), Bryan J. Schneider(Georgetown University), Elizabeth Blanchard(American Society of Clinical Oncology), Narjust Florez(Dana-Farber Cancer Institute), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Pamela R. Moffitt(American Society of Clinical Oncology), Natasha B. Leighl(Princess Margaret Cancer Centre), Andrew Robinson(University of California, Riverside), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Paul Celano(Greater Baltimore Medical Center), Erin L. Schenk(University of Colorado Anschutz Medical Campus), Tanyanika Phillips(Georgetown University), Gregory A. Masters(Christiana Care Health System), Lecia V. Sequist(Harvard University), Nofisat Ismaila(American Society of Clinical Oncology), Navneet Singh(Post Graduate Institute of Medical Education and Research)
Cited by 32
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k